{
  "id": 6399234,
  "title": "Evommune's MRGPRX2 antagonist flunks its second I&I trial this summer",
  "url": "https://urgent.news/2026/09/09/evommunes-mrgprx2-antagonist-flunks-its-second-i-i-trial-this-summer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-09T07:38:48.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/evommunes-mrgprx2-antagonist-flunks-its-second-ii-trial-this-summer/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Evommune's Dermira-derived small molecule has failed a Phase 2b test in atopic dermatitis, marking the second mid-stage flop for the experimental drug this summer. The Palo Alto biotech",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}